Artivion reported second-quarter 2026 revenue of $125.8 million, up 9% on a constant currency basis, driven by growth in heart valve and stent graft products. Adjusted EBITDA rose 7% to $26.4 million, while adjusted EBITDA margin declined 90 basis points to 21% due to increased R&D investment and the Endospan acquisition. Stent graft revenue grew 12% to $46.4 million, On-X valve revenue increased 18% to $30.5 million, preservation services revenue rose 1% to $25.9 million, and surgical sealant revenue fell 2% to $19.3 million. The company received U.S. FDA premarket approval for its AMDS hybrid prosthesis in late June and completed the acquisition of Endospan during the quarter, adding the NEXUS Aortic Arch Stent Graft System. Full-year revenue guidance was reiterated at $480 million to $496 million, representing adjusted constant currency growth of 7% to 11%, and full-year adjusted EBITDA guidance was reiterated at $92 million to $99 million.
Artivion IncRevenue growth driven by heart valve and stent graft products, with On-X valve up 18% and stent graft up 12%.
